Redhill Biopharma Rises 4.37% as Pipeline & Valuation Gap Ignite Investor Interest
Redhill Biopharma (RDHL) jumps 4.37%, beating a market downtrend and showing early pre‑clinical promise, regulatory clarity, and partnership buzz—value‑seeking investors watch closely.
3 minutes to read